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QbD approachAbstract A method has been developed for the separation of moxiﬂoxacin HCl and ketorolac tro-
methamine using reverse phase high-performance liquid chromatography (RP-HPLC) on C18 col-
umn (250 · 4.6 mm, 5 lm) with UV detection at 308 nm. Experimental designs were applied for
multivariate optimization of the experimental conditions of RP-HPLC method. Three independent
factors: methanol content in the mobile phase composition, buffer pH and ﬂow rate were used to
design mathematical models. Here faced central composite (FCC) experimental design was used to
study the response surface technique and to study in depth the effects of these independent factors.
Derringer’s desirability function was applied to simultaneously optimize the retention time of last
eluting peak (ketorolac tromethamine) and tailing factor of moxiﬂoxacin. The predicted optimum
assay condition consisted of methanol and potassium dihydrogen phosphate buffer (pH 3.2;
25 mM, 0.5% Triethylamine) in a proportion of 60:40% v/v, respectively, as the mobile phase at
a ﬂow rate of 1.2 mL min1. Using this optimum condition, baseline separation of both drugs with
good resolution and a run time of less than 7 min were achieved. The optimized assay condition was
validated according to ICH guidelines to conﬁrm speciﬁcity, linearity, accuracy and precision.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Moxiﬂoxacin hydrochloride (MOXI), chemically known as [1-
cyclopropyl-6-ﬂuoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octa-
hydro-6H-pyrrolol(3, 4b)pyridin-6-yl]-4-oxo-3-quinoline carboxylic
acid] hydrochloride, is shown in Fig. S1a (See, supplements).
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with extended-spectrum of in vivo and in vitro activity against
Gram-positive and Gram-negative bacteria [1]. Ketorolac
tromethamine (KETO), [(6)-5-benzoyl-2,3 dihydro-1H-
pyrrolizine-1-carboxylic acid], is shown in Fig. S1b (See, sup-
plements). It is a nonsteroidal anti-inﬂammatory drug
(NSAID) with analgesic efﬁcacy 800 times more potent than
acetylsalicylic acid (aspirin). It has both anti-inﬂammatory
and analgesic activity [2]. KETO is mainly used in the treat-
ment of postsurgical ocular pain, allergic conjunctivitis [3]. A
combination of MOXI and KETO is used as anti-infective
and antiseptic in the form of eye drops. MOXI and KETO
are ofﬁcial in British Pharmacopoeia (BP) and United State
Pharmacopoeia [4] but combination is not yet ofﬁcial in any
pharmacopoeia. The ofﬁcial monographs describe the proce-
dure for individual assay of MOXI and KETO using
RP-HPLC and potentiometry, respectively [5].
Moreover, the extensive literature survey revealed that
there is no RP-HPLC method available for simultaneous esti-
mation of MOXI and KETO combination in the pharmaceu-
tical dosage forms using experimental design approach
(Quality by Design). A few analytical and bioanalytical meth-
ods have been reported in the literature for the determination
of MOXI or KETO alone or combination with other drugs.
They include spectrophotometric methods for MOXI in phar-
maceutical dosage form [6] and other methods like high-per-
formance liquid chromatography (HPLC) with ﬂuorescence
[7,8] or UV detection [9]. Voltametry [10] and capillary electro-
phoresis with laser-induced ﬂuorescence [11] were also
reported for determination of MOXI from human body ﬂuids.
MOXI was estimated with other ﬂuoroquinolones using
HPLC from human plasma [12]. Some analytical procedures
have been reported for quantitative determination of KETO
alone by using HPLC method [13,14], KETO and its impuri-
ties were detected by capillary electrochromatography [15]
and assay of KETO in pharmaceutical matrices using differen-
tial pulse polarography [16]. Recently one article is published
for validated stability-indicating high performance liquid chro-
matographic method for MOXI and KETO using ACE C18
column (5 lm, 150 mm · 4.6 mm) with potassium di-hydrogen
phosphate buffer pH 4.6-Acetonitrile (75:25 v/v) at a ﬂow rate
of 1.0 mL min1. [17]. This method has a run time of more
than 10 min as well as does not describe the design space or
interaction study of independent factors as per recent FDA
guidelines [18]. Regulatory authorities (FDA, ICH, etc.) are
promoting and requesting the application of experimental
design approach to understand chromatographic selectivity
and support better method control, including method transfer.
This prompted the researchers to adopt the experimental
design in HPLC and many papers were published related to
this work [20,19,21,22,23,24].
The main objective of our work is to develop an improved
RP-HPLC method suitable for the routine quality control of
MOXI and KETO in a pharmaceutical industry and provide
information on the sensitivity of chromatographic factors
and their interaction effects on the separation characteristics.
The optimization of chromatographic factors likes methanol
concentration in mobile phase, buffer pH and ﬂow rate are
very complex that have signiﬁcant effect on chromatographic
separation. All these independent factors can easily be opti-
mized using the design of experiments that is called Quality
by Design (QbD) approach. Quality by Design is a systemicapproach that includes multi-dimensional combinations and
input variables using Design of Experiment to obtain the opti-
mum conditions with good assurance of quality. Design space
is generated through experimental design that shows the ﬂexi-
ble region in which post approval changes are not required
during any of changes in the parameters (e.g. pH, % of organic
modiﬁer, etc.) (ICH Q8 (R2) [25]). When one needs to optimize
more than one response (retention time and tailing factor of
both the drug peaks) at a time the use of Derringer’s desirabil-
ity function is the best choice. Derringer’s desirability function
was ﬁrst used in chromatography by Deming [26]; to get better
resolution and shorter analysis time as objective functions to
get better separation quality. We have employed the same
methodology for the development and optimization of a new
HPLC method for the simultaneous estimation of MOXI
and KETO from an eye drop formulation.
2. Experimental
2.1. Materials
Pure MOXI and KETO were obtained from Aurobindo and
Symed Lab, Hyderabad, India respectively as a gift sample.
Methanol (MeOH) was of HPLC grade, potassium dihydrogen
phosphate and phosphoric acid were of analytical-reagent
grade supplied by M/S SD Fine Chemicals (Mumbai, India).
HPLC grade water was obtained following distillation in glass
and passage through a Milli-Q Academic system (Millipore,
Bangalore, India) and was used to prepare all solutions. Mil-
ﬂox Plus eye drop formulation was purchased from local
pharmacy. This formulation has a label claim of 0.5% w/v
of MOXI and KETO each. It also may contain isotonicity
modiﬁer sodium chloride, buffering agents like boric acid or
monobasic sodium phosphate and preservatives like benzalko-
nium chloride and chlorobutanol.
2.2. Instrumentation
A Shimadzu HPLC instrument- LC-20AD (Japan) equipped
with Rheodyne 7725i injection valve with a 20 lL loop volume
and Binary gradient pump was used. The system also includes
a UV–VIS (Shimadzu, SPD-20A) detector operated at a wave-
length of 308 nm. Data were acquired and processed by using
LC-solution software. Chromatographic separation was per-
formed using Grace Smart RP C18 column (250 mm · 4.6 mm,
5.0 lm).2.3. Software
Experimental design (Faced central composite), desirability
function and data analysis calculations were performed by
using Design-Expert version 8.0.4.1.2.4. Preparation of standard stock solution
About 100 mg of MOXI and 100 mg of KETO were accurately
weighed and transferred into 100 mL volumetric ﬂask. The
contents of the volumetric ﬂask were dissolved in mobile phase
to get 1 mg mL1 of both MOXI and KETO. Working stan-
dard solution was freshly obtained by diluting the standard
Table 1 Experimental factors and levels used in the central
composite design.
Factor Name Level () Level (0) Level (+)
A Flow rate (mL min1) 0.8 1 1.2
B Buﬀer pH 3.2 3.5 3.7
C Methanol (% v/v) 50 55 60
Determination of Moxiﬂoxacin HCl and Ketorolac tromethamine in eye drops S375stock solution with mobile phase during the analysis time. The
stock solution and working standard solution were protected
from light during analysis.
2.5. Chromatographic procedure
Chromatographic separations were carried out on a Grace
Smart RP C18 column (250 mm · 4.6 mm, 5.0 lm). A mixture
of methanol and potassium dihydrogen phosphate (25 mM
KH2PO4) was used as the mobile phase. The pH of the buffer
was adjusted with phosphoric acid (H3PO4). In order to
decrease the tailing of MOXI peak 0.5% triethylamine
(TEA) was used as ion pairing agent in the mobile phase,
which prevents the interaction of MOXI with free silanol of
stationary phase. Wavelength of 308 nm was used as detection
at which both drugs gave good response.
2.6. Experimental design and response surface methodology
The experimental design approach can be useful to optimize
the separation and to help out in the development of better
understanding of the interaction of several chromatographic
factors on separation quality. To begin the development of a
QbD acquiescent analytical method and ﬁnally reach the deﬁ-
nition of its Design Space (DS) and optimization of method, a
number of steps are illustrated in Scheme 1 which shows total
four steps to complete the method. The ﬁrst step is to identify
the goal of the intended method that depends on the types of
method developed such as for routine quality control assay
method should be fast, accurate and speciﬁc. Hence, we set
the same goal for our assay method. The second step is the
assessment of critical factors that affect on the critical quality
attributes (CQA) like in HPLC resolution, run time, tailing of
peak, etc. The third step is creation of experimental design and
mathematical model that expresses the relation between the
factors and response. In this work, the important chromato-
graphic factors were selected based on preliminary experiments
and prior knowledge from the literature and optimized by a
central composite design (CCD) experiment. A CCD design
was employed to locate the optimum ﬂow rate, mobile phase
pH, % of organic modiﬁer for separation by mapping the
chromatographic response surface. Table 1 shows three chro-
matographic factors and levels selected in which experimental
condition was optimized. To provide a Faced Central•How much Run 
time, Accuracy 
or Precision, 
etc. required?
Identify Analytical 
method goal
•Identify the 
critical factors 
•e.g. in HPLC; 
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Scheme 1 Graphical representation of method devComposite Design (FCCD) for three independent variables,
a partial factorial design was combined with ﬁve replicates of
center points and ﬁve axial points at an extreme level. The sec-
ond order model was ﬁtted to the experimental results. The
qualities of the ﬁtted polynomial models were examined on
the basis of the coefﬁcient of determination R2. The position
of the true optimum condition was recognized by applying
Derringer’s desirability function, where responses were simul-
taneously optimized. The ﬁnal step is to predict the response
and design space from the polynomial equation.
Response surface methodology (RSM) is a mathematical
and statistical technique valuable for analyzing problems
where several independent variables like column temperature,
pH, ﬂow rate, etc. affect dependent variables or responses
(e.g. resolution, tailing of peak, run time). This technique is
used to simultaneously optimize the levels of these variables
to attain the best system performance. RSM enables deﬁnition
of quadratic models that accurately explain the response for all
values of the chromatographic conditions in the experimental
region. For calculation of quadratic regression model coefﬁ-
cients, each design variable must be studied, at least at three
distinct levels and consequently, a CCD was used in this opti-
mization study [27].
3. Results & discussion
3.1. Method development and optimization
MOXI and KETO are medium-polar analytes because of the
carboxyl group with phenyl moiety. Hence, reverse phase
mode is more preferable than normal phase. Initially, we tried
different reverse phase columns like C18, cyano and C8 for
separation of both analytes. But cyano column showed poor
separation of both analytes while in C8, moxiﬂoxacin was elut-eate experimental 
sign and 
thematical model 
Design 
generation
•Generate the 
design space 
•Prediction of 
response using the 
multivariate model
Design space & 
prediction
Optimization of 
method and 
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elopment ﬂow using quality by design approach.
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only C18 column for optimization study. Fig. S2 (See, supple-
ments) shows the overlay UV spectra of both drugs, which
indicates that 308 nm is the optimum wavelength to detect
MOXI and KETO with good response as well as minimum
base line noise. The mobile phase pH is an important factor
that drives the selectivity of the method due to differences in
the pKa of molecules. Initial method development was tried
on three different pH 3.5, 4.5 and 5.5 based on the literature
report [17]. However, high tailing (>2) was observed with
MOXI at pH 4.5 and 5.5 and mild tailing at pH 3.5 due to
the interaction between a positively charged solute (amine of
MOXI) and a negatively charged silanol on the surface of silica
stationary phase at pH 4.5 and 5.5. It is observed most often
when using HPLC columns packed with stationary phases that
have signiﬁcant silanol activity. It is usually worse in a basic
pH mobile phase than in an acidic pH mobile phase because
pKa of silanol groups is around 3.5, therefore above pH 3.5 sil-
anol groups are in ionized form and ready to interact with 1,
2 amines. Therefore, TEA was added to inhibit MOXI peak
tailing due to the interaction of a free silanol group. TEA acts
as competing base, reducing the availability of stationary
phase free silanols and interaction of the analyte with the sila-
nols. The concentration of TEA should be optimum because at
high concentration it is signiﬁcantly difﬁcult to wash off the
columns and long equilibration time between the runs. We
tried at different concentration of TEA from 0.1% to 1%
for optimization. TEA concentration was optimized to 0.5%
(keeping the constant pH at 3.5) at the same time as above
0.5% of TEA was not signiﬁcantly affect the symmetry of
MOXI peak as well as lower than 0.5% was not reducing
the tailing of peak (Fig. 1). Mainly organic modiﬁers for
reversed-phase include acetonitrile, methanol, and in some
cases, tetrahydrofuran. Due to the high UV cut off as well as
presence of peroxide impurities in tetrahydrofuran that affect
the stability of analytes, hence tetrahydrofuran was avoided
for selection of organic modiﬁer. We have used methanol
because of its cost, good solubility in all buffers and it acts
as Lewis acid by donating hydrogen that improves the peak
shape of MOXI.3.2. Design of experiment and design space
The design matrix generated for the Faced Central Composite
Design is shown in Table 2 and the system was fully optimized
using the 15 experiments. This design is composed of a two
level factorial design with additional center points that are
located at the center of the experimental region. In this study,
the levels of each factor were selected based on prior scouting
experiments. Many more experiments would have been
required if this method was optimized with the standard uni-
variate approach. Initially, it was found that at below
0.8 mL min1 ﬂow rate peaks became broad and above
1.2 mL min1 proper separation was not observed. In the same
way, ideal MeOH concentration was found in between 50% v/
v and 60% v/v. If any C18 column works consistently at pH
3.0 that reduces the column shelf life therefore, keeping this
in mind we tried to optimize the pH range in between 3.2
and 3.7. As can be seen in Table 2, the ranges of each factor
were: ﬂow rate (0.8–1.2 mL min1), buffer pH (3.2–3.7) and
MeOH concentration (50–60% v/v). Here, our main goal isto develop the method with minimum run time as well as
symmetric peak shape of MOXI that facilitate the accurate
quantiﬁcation of drugs within a short period. Hence, retention
time of last eluting peak (KETO Rt) and tailing of MOXI (T)
were taken as response. The statistical parameters obtained
from ANOVA for the regression models are listed in Table 3.
Probability P< 0.05 was obtained, implying that these models
are signiﬁcant. Adjusted R2 was well within the acceptable lim-
its (R2 > 0.8) that shows experimental model is good ﬁt with
polynomial equations. The adequate precision value is a mea-
sure of the ‘‘signal (response) to noise (deviation) ratio’’ that
should be greater than four. In this study, the ratio was found
to be greater than 25, which indicates an adequate signal and
therefore the model is signiﬁcant for the separation process.
The reproducibility of the model depends on the coefﬁcient
of variation (C.V.) that is well within the limit of both
responses (% C.V. < 10) [28].
Table 3 illustrates the interaction term with the largest abso-
lute coefﬁcients among the ﬁtted models is 0.61AC of Rt model.
The positive interaction between A and C is statistically signiﬁ-
cant (P= 0.001) for Rt. The study reveals that changing the
fraction of MeOH from low to high results in a rapid decline
in Rt both at the low and high level of buffer pH. Further, at
the low level of factor A, an increase in the buffer pH results in
a marginal decrease in the retention time of KETO (Rt). There-
fore, whenMeOHconcentration is set at its lowest level, the buf-
fer pH has to be at its highest level to shorten the analysis time.
Especially this interaction is synergistic, as it led to a decrease in
analysis time. The second response model T reveals that all fac-
tors affect moderately on the tailing of MOXI.
In order to get a better understanding of the results, the
perturbation plots [29] are presented in Fig. 2. For an optimi-
zation design, this graph shows how the response changes as
each factor moves from a chosen reference point, with all other
factors held constant at the reference value. A steep slope or
curvature in a factor indicates that the response is sensitive
to that factor. Fig. 2b reveals that as methanol concentration
in mobile phase decreases, tailing of MOXI peak reduces due
to decline in the interaction with free silanol groups of column.
Design space was generated after processing all data using
the modeling software Design Expert@. Two dimensional
color maps are represented in Fig. 3 that shows high retention
time and tailing with warm ‘‘red’’ and low retention and tailing
of peak with cold ‘‘blue’’ colors. From the constructed Design
Space the working point was selected by visual examination
looking for the least retention time (of KETO) and tailing of
peak (of MOXI). Fig. 3a and b shows that retention time of
KETO increased toward the pH 3.2, ﬂow rate 0.8 mL min1
and % of MeOH 50%. At the same time, tailing of MOXI
peak was decreased toward acidic pH and low methanol con-
tent. As per our method’s goal, at pH 3.2, % of MeOH 60%
v/v and ﬂow rate of 1.2 mL min1 satisfy faster separation
(<7.0 min) with good resolution (Rs > 12.0) and optimum
tailing of MOXI peak (T= 1.26).3.3. Derringer’s desirability function
Our objective was to maximize resolution with symmetric peak
and to minimize analysis time. Hence, when there are multiple
responses to optimize with different targets, Derringer’s
desirability function is a suitable technique. The Derringer
Figure 1 Effect of triethylamine (TEA) on the peak symmetry of MOXI.
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weighted, or otherwise, of the individual desirability functions
[30].
Value of D different from zero implies that all responses are
in a desirable range simultaneously and consequently, for a
value of D close to 1, the combination of the different criteria
is globally optimal, so that the response values are near target
values.
The criteria for the optimization of each individual
response are shown in Table 4. Criteria have been proposed
for selecting an optimum experimental condition for analyzing
routine quality control samples. Generally, a short analysis
time is usually preferred for routine analysis. Hence, high
importance (value 4) was assigned to retention time (Rt) of last
eluting peak. Following the conditions and restrictions above,
the optimization procedure was carried out using Design
Expet@. The response surface plot obtained for the maximum
desirability function (D= 0.984) is presented in Fig. 4, whichindicates our mathematical model is excellent. The coordinates
produce the maximum desirability value at MeOH 60% v/v,
buffer pH 3.2, and ﬂow rate of 1.2 mL min1. The predicted
response values corresponding to the above optimum condi-
tion are given in Table 5.4. Method validation
4.1. Speciﬁcity
The speciﬁcity of the method was evaluated after analyzing the
placebo containing both MOXI and KETO at a concentration
of 1.0 lg mL1 each. The placebo consisted of preservatives:
benzalkonium chloride and chlorobutanol; isotonicity modi-
ﬁer: sodium chloride; thickening agents: corboxy methyl cellu-
lose, poly ethylene glycol and poly vinyl alcohol; and buffering
agents like boric acid and monobasic sodium phosphate. No
Table 2 Central composite design data matrix and responses.
Design points Factor levels Responses
Sample pH FR (mL min1) MeOH (% v/v) Rt (min) (KETO) T (MOXI) Total run time (min)
1 3.7 1 55 8.800 1.387 9
2 3.2 1 55 9.630 1.259 10
3 3.45 1.2 55 7.524 1.275 8
4 3.45 0.8 55 10.953 1.317 11
5 3.45 1 60 6.576 1.356 7
6 3.45 1 50 13.176 1.215 14
7 3.2 0.8 50 17.580 1.135 18
8 3.7 0.8 50 13.369 1.41 14
9 3.2 1.2 50 12.071 1.118 13
10 3.7 1.2 50 9.447 1.312 10
11 3.2 0.8 60 8.714 1.316 9
12 3.7 0.8 60 7.48 1.456 8
13 3.2 1.2 60 5.885 1.29 6
14 3.7 1.2 60 5.137 1.394 6
15 3.45 1 55 8.938 1.2 9
FR= ﬂow rate of mobile phase in mL min1.
Rt = retention time of ketorolac tromethamine.
T= tailing of moxiﬂoxacin hydrochloride.
Table 3 Regression model and statistical parameters obtained from ANOVA.
Response Regression model Adjusted R2 Model P-value % C.V. Adequate precision
Rt 9.69  0.96A  1.8B  3.19C + 0.26AB+ 0.61AC+ 0.53BC 0.9650 <0.0001 6.36 28.28
T 1.3 + 0.083A  0.024B + 0.063C  0.013AB  0.027AC 0.9618 <0.0001 1.42 26.962
A – ﬂow rate; B – buffer pH; C – % MeOH.
Figure 2 Perturbation plot showing (a) the effect of each of the independent factors on Rt of KETO and (b) the effect of each of the
independent factors on tailing (T) of MOXI, while keeping other factors at their respective mid-point levels [A: pH = 3.5; B: ﬂow
rate = 1.0 mL min1; C: % MeOH= 55% v/v].
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generally used in eye drop formulations.
4.2. Linearity
The Linearity was established at the concentration range of
1–10 lg mL1 for MOXI and KETO. The standard stocksolution was diluted with mobile phase to get 1, 2, 4, 6, 8
and 10 lg mL1 of both MOXI and KETO. Each concentra-
tion was analyzed in 3 replicates. Peak areas (y) of MOXI or
KETO were plotted versus their respective concentrations (x)
and linear regression analysis performed on the resultant cali-
bration curves. Linearity data are shown in the Table S1 (See,
supplementary information).
Figure 3 2-D model shows (a) design space for retention time of KETO in pH_Flow rate model (b) design space for retention time of
KETO in pH_% of MeOH model (c) design space for tailing of MOXI peak in pH_Flow rate model (d) design space for tailing of MOXI
peak in pH_% of MeOH model.
Table 4 Optimization of the individual responses for the analysis of quality control Samples.
Response Lower limit Upper limit Weight Criteria
Goal Relative importance
Rt (min) 5.14 17 1 Target = 6 4
T 1.12 1.5 1 Range 2
Figure 4 Graphical representation of the overall desirability
function D. Flow Rate (B) is plotted against pH (A) with
MeOH% v/v (C) held constant at 60% v/v.
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Accuracy of the method was determined by performing the
recovery experiment at 80%, 100% and 120% of the expected
assay value or label claim of the drugs in the commercial eye
drops. To the placebo 4 mg mL1 (80%), 5 mg mL1 (100%)
and 6 mg mL1 (120%) of both MOXI and KETO were added
and analyzed by the proposed method in 3 replicates at each
level. The % mean recovery of drugs at each level was deter-
mined (Table S2, supplementary information). The recoveries
of MOXI and KETO at each level were found to lie well within
the acceptable criteria of bias ±2% [32].
4.4. Limit of detection and quantitation
LOD and LOQ for both MOXI and KETO were determined
according to ICH guideline Q2 (R1) [31]. LOD was deﬁned
as 3.3 r/S and LOQ as 10 r/S based on, standard deviation
Table 5 The comparison of experimental and predictive values of different objective functions under optimal condition.
MeOH% v/v Flow rate (mL min1) Buﬀer pH Rt (min) T Total desirability
60 1.2 3.2 Experimental value 5.9 1.26 0.984
Predicted value 6.0 1.32
MeOH=methanol; T= tailing.
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structed at six levels ranging 0.5–1.0 lg mL1 of both MOXI
and KETO (Table S1, supplementary information). LOD
and LOQ results are given in Table S1 are were experimentally
veriﬁed (Fig. 6).
4.5. Precision
Precision was determined by studying the intermediate preci-
sion and repeatability. Repeatability expresses the precision
under the same operating conditions over a short interval of
time. Repeatability is also termed intra-assay precision. Inter-
mediate precision expresses within-laboratories variations: dif-
ferent days, different analysts, different equipment, etc.
Intermediate precision is also termed inter-assay precision.
The intra-day and inter-day assay precision was studied at
1.0 lg mL1 concentration level (n= 5) and precision wasFigure 5 Chromatogram of Milﬂox Plus eye drops containing M
buffer pH = 3.2, Flow rate = 1.2 mL min1).
Figure 6 LOQ level chromatogrconﬁrmed as the % RSD was well within the target criterion
(<2%). Precision is given in Table S3 (See, supplementary
information).
5. Application of the method in marketed formulation
The proposed method was applied to three batches of mar-
keted eye drops (Milﬂox Plus) for determining the content
of MOXI and KETO. About 1.0 mL of eye drop formulation
was transferred to a 100 mL volumetric ﬂask and was diluted
up to the mark with the mobile phase. This solution was fur-
ther diluted to get a nominal concentration of 5 lg mL1 of
both the drugs. Similarly two more samples were prepared
from another two batches of same formulation and each sam-
ple was analyzed in two replicates. Representative chromato-
gram and percentage label claim of drugs in the formulations
are shown in Fig. 5 and Table 6, respectively. The % RSDOXI and KETO under optimum condition. (Methanol = 60%,
am of ﬁnal optimized method.
Table 6 Application of optimized method in marketed formulation (Milﬂox Plus) (n= 3).
Marketed eye drops MOXI (% label claim) KETO (% label claim) % RSD
Batch 1 98.92 99.54 0.12
Batch 2 99.27 100.35 0.26
Batch 3 100.23 99.78 0.58
RSD= relative standard deviation.
Determination of Moxiﬂoxacin HCl and Ketorolac tromethamine in eye drops S381of the assay results was less than 2%, which indicates the
method is precise.
6. Conclusion
Statistically based experimental designs proved to be an impor-
tant approach in optimizing selectivity-controlling parameters
for the simultaneous determination of MOXI and KETO in
commercial formulation. The signiﬁcant factors were opti-
mized by applying central composite design and response sur-
face methodology. The objective responses, tailing factor and
the analysis time, were then simultaneously optimized by
applying Derringer’s desirability function, a multi-criteria deci-
sion making tool. This method has been evaluated for linear-
ity, precision, accuracy and selectivity, and has proved to be
convenient and effective for the quality control of MOXI
and KETO in eye drops. Moreover, the previously reported
method addresses only separation of both drugs with tradi-
tional approach with longer run time of >9.0 min by using
150 mm length columns (5 lm particle size) while our pro-
posed method is able to quantify MOXI and KETO in a run
time of <7 min using novel approach, multivariate statistic
techniques.
The experimental design and response surface technique
procedure provides a better insight into the sensitivity of chro-
matographic factors and their interaction effects on the attri-
butes of separation. It also gives an opportunity to the
chromatographer to customize the objective responses depend-
ing on the nature of the matrices in which the analyses need to
be performed. The improved method showed higher sensitivity
of 0.098 lg mL1 for MOXI and 0.090 lg mL1 for KETO.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jscs.2014.
04.004.
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